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Abstract
Background: MicroRNAs are a class of small non-coding RNAs that regulate mRNA expression at the post - 
transcriptional level and thereby many fundamental biological processes. A number of methods, such as multiplex 
polymerase chain reaction, microarrays have been developed for profiling levels of known miRNAs. These methods 
lack the ability to identify novel miRNAs and accurately determine expression at a range of concentrations. Deep or 
massively parallel sequencing methods are providing suitable platforms for genome wide transcriptome analysis and 
have the ability to identify novel transcripts.
Results: The results of analysis of small RNA sequences obtained by Solexa technology of normal peripheral blood 
mononuclear cells, tumor cell lines K562 and HL60 are presented. In general K562 cells displayed overall low level of 
miRNA population and also low levels of DICER. Some of the highly expressed miRNAs in the leukocytes include several 
members of the let-7 family, miR-21, 103, 185, 191 and 320a. Comparison of the miRNA profiles of normal versus K562 
or HL60 cells revealed a specific set of differentially expressed molecules. Correlation of the miRNA with that of mRNA 
expression profiles, obtained by microarray, revealed a set of target genes showing inverse correlation with miRNA 
levels. Relative expression levels of individual miRNAs belonging to a cluster were found to be highly variable. Our 
computational pipeline also predicted a number of novel miRNAs. Some of the predictions were validated by Real-time 
RT-PCR and or RNase protection assay. Organization of some of the novel miRNAs in human genome suggests that 
these may also be part of existing clusters or form new clusters.
Conclusions: We conclude that about 904 miRNAs are expressed in human leukocytes. Out of these 370 are novel 
miRNAs. We have identified miRNAs that are differentially regulated in normal PBMC with respect to cancer cells, K562 
and HL60. Our results suggest that post - transcriptional processes may play a significant role in regulating levels of 
miRNAs in tumor cells. The study also provides a customized automated computation pipeline for miRNA profiling and 
identification of novel miRNAs; even those that are missed out by other existing pipelines. The Computational Pipeline 
is available at the website: http://mirna.jnu.ac.in/deep_sequencing/deep_sequencing.html
Background
Small non-coding RNAs participate in a variety of pro-
cesses from cell development and differentiation, stress
responses to carcinogenesis by regulating gene expres-
sion [1-4]. Regulatory non-coding RNAs have been
reported from almost all organisms from bacteria to
mammals [5]. Among the various classes of non-coding
small RNAs (sRNAs), the most conserved and prominent
ones are the microRNAs or miRNAs [for a recent review
see, [6]]. Mature miRNA sequences are single stranded,
typically 18-24 nucleotides long and encoded as a precur-
sor molecule of about 60-120 nucleotides (in humans) [7].
These precursors are derived from processing pri-
miRNA (usually in kilobases) by a ribonuclease, such as
DROSHA [8]. Pre-miRNAs are also further cleaved to
generate active mature miRNAs with the help of DICER
[9]. So far more than 800 miRNAs have been described in
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Page 2 of 18human [10]. miRNAs interact with 3'UTR of mRNAs
through base pairing and bring about their degradation,
destabilization, or repression of translation through
RISC, a complex of multiple proteins and miRNA-mRNA
adduct [11,12]. Occasionally it can also up regulate gene
expression [13].
The expression profiles of miRNAs have been deter-
mined in order to understand the role of miRNAs in a
specific biological process [14]. The profiles generated
revealed altered levels of miRNAs in different systems,
such as oncogenesis and development [15,16]. These
studies showed strong correlation between specific
miRNA expression and phenotype suggesting it can be
used as a potential biomarker for diagnosis and prognosis
in human cancer [17]. Several groups of miRNAs have
been identified that regulate the expression of tumor-
associated genes while others seem to hold prognostic
value in predicting patient survival. For example, miR-21
is frequently over expressed in various cancers [18]. It is
now considered as an oncomiR that acts by down regulat-
ing PTEN, a tumor suppressor gene [19]. Similarly let-7
family of miRNAs is frequently down regulated in lung
cancers [20]. miR-15a and 16-1 are often deleted in
chronic lymphocytic leukemia [21]. These miRNAs target
RAS, HMGA2 and BCL2 oncogenes, respectively,
thereby regulating tumorigenesis [22-24]. Expression of
let-7a, miR-210 and miR-200 clusters was demonstrated
to be a strong prognostic marker for lung cancer, breast
cancer and ovarian cancer, respectively [25-27]. Many of
the fundamental processes are regulated by miRNAs,
such as cell differentiation (miR-223, miR-145) [28,29],
apoptosis (miR-34, miR-16) [21,30], body patterning
(miR-9, miR-196) [31,32], nervous system and muscle
development (miR-134, miR-1 and miR-133) [33,34].
A number of different approaches have been used for
expression profiling, such as northern analysis [35], clon-
ing [36], real time polymerase chain reaction [37],
microarray analysis [38,39] and RNase protection assay
[25,40]. These methods are not generally useful for dis-
covery and expression profiling of low-abundance tran-
scripts or yet unidentified novel miRNAs. Recently a
number of different platforms have been developed for
carrying out large scale parallel sequencing in order to
generate genome wide sequences in a short time and
reduced cost [41-43]. These have also been applied to
analyze transcriptome including sRNA sequences [41].
Generally sequences derived using these platforms can be
processed to generate expression profiles of known genes
and suitable computational methods can be employed to
identify unknown genes. Some of these platforms along
with custom computation pipelines have been used to
study sRNAs from different systems, such as plants,
human embryonic cells and developing chicken embryo
[44-46]. All these studies not only generated expression
profiles of known miRNAs but also identified a few novel
miRNAs. Morin et al. used this strategy in combination
with RNAfold, MiPred and an in house SVM model to
identify novel miRNAs [47]. Though the study identified
104 novel miRNAs there was no attempt to verify these
by other experiments. A software pipeline miRDeep has
been developed to analyze large-scale sRNA sequencing
data and identification of novel miRNAs [48]. Some of
the filters used in this approach are highly stringent and it
is likely that many novel miRNAs may be missed. Genera-
tion of expression profiles and identification of novel
miRNAs from deep sequencing is dependent on tools
used for analysis. It appears from this discussion that
there is a need for development of efficient automated
pipelines for analysis of deep sequencing data and setting
up validation pipeline for checking the results, as newer
algorithms may allow improved profiling and identifica-
tion of novel miRNAs.
In this manuscript we have profiled sRNA expression
from normal human peripheral blood mononuclear cells
and two cancer cell lines using Solexa technology and
developed automated computation pipelines for analyz-
ing quantitative expression. Our pipelines use statistical
analysis of the Solexa sequences for generation of expres-
sion profiles and a number of different methods for pre-
diction of novel miRNAs. We believe that these pipelines
are highly robust and can be useful for other studies.
Results
Sequencing and Annotation of Small RNAs
sRNAs were size selected by gel electrophoresis and then
sequenced using a Solexa platform (Illumina, USA). The
details of sequencing reads of the four samples are given
in Additional file 1. The length of an average read was
about 33-35 nucleotides. The processing of the raw
sequences through computation pipeline is outlined in
Figure 1 and described in "Methods". Briefly, the adaptor
sequences were first removed from the sequence reads.
Only those reads that were greater than 10 nucleotides
were considered for further analysis. These sequences
were clustered on the basis of sequence similarity and
subjected to similarity searches using specific databases
(rRNAs, tRNA, sn/snoRNAs, miRNAs, other non-coding
RNAs). The reads that did not match known RNA
sequences were checked to see if these were encoded by
intergenic, intronic or exonic regions of the human
genome (Figure 2).
Sequencing reads derived from mRNAs and rRNAs
made up about 2-4 and 2-13% of the total reads of all the
samples, respectively except that from K562 cells. Since
mRNAs and rRNAs are likely to have been derived by
degradation it appears that the degradation was minimal
in these samples. The sequencing reads derived from
miRNAs were estimated to be about 60-80%, similar to
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K562 was quite different. Only about 18% of total sRNA
population was found to be derived from miRNA. Low
level of miRNAs in K562 cells is unlikely to be due to arti-
fact as we got similar values in two independent experi-
ments (data not shown). Out of a total of 904 miRNAs
(718 major and 186 star sequences) present in miRBase
version 14, 534 miRNAs were detected in at least one of
the four samples sequenced [49]. A total of 370 miRNAs
were not detected in any of the samples.
MicroRNA expression patterns
Absolute sequence reads were transformed into tran-
script abundance by first normalizing the data in 'tran-
scripts per million (TPM)' for each library (see
"Methods"). The expression levels ranged from less than
10 to more than 100,000 counts (Figure 3, refer Addi-
tional file 1). Thus the sequencing data revealed a wide
range of expression levels spanning five orders of magni-
tude. Several members of the let-7 family, 103, 185 and
320a were observed as some of the highly expressed miR-
NAs (Figure 4). These miRNAs were also reported as
highly abundant miRNAs in peripheral blood mononu-
clear cells using "Taqman microRNA assay" [50]. While
the members of let-7 family, let-7a, f and g represented
about 77% of the total miRNA counts, a number of miR-
NAs with less than 10 counts including singletons were
also noticed (Additional file 1). It is not clear if the single-
tons represent true transcript or noise of the system.
miR-219-5p was one of the singletons found in all the
four samples suggesting that such sequences may not be
due to experimental noise or a chance event. Star
sequences of many miRNAs (20% of all known miRNAs)
were also observed mostly at low abundance level. Some
of the highly abundant star sequences observed by us
were miR-106-b* (N1, TPM- 288.28); miR-17* (N1, TPM-
1321.41); miR-92a-1* (N1, TPM- 942.78), miR- 25* (N1,
Figure 1 Flowchart describing the elimination pipeline used to 
filter out the indicated sequences from the library of sRNA se-
quences. The sequences were matched using an "in house" devel-
oped fast algorithm. Alignment with maximum of two mismatches 
was considered as hits. All the hits were removed before the next 
round of elimination. The databases used in this pipeline were either 
generated in house or downloaded from publicly available sites as de-
scribed in "Methods".
Figure 2 Frequency of different classes of RNA species present in sRNA libraries. The sequences obtained from the sRNA libraries were subject-
ed to a series of sequence similarity searches using specific databases (rRNAs, tRNA, sn/snoRNAs, miRNAs, other non-coding RNAs) and the pipeline 
described in Figure 1. The sequences that did not match with any known sequence were matched against databases of intergenic and intronic re-
gions of the human genome. The pie-charts represent an overview of small RNA gene expression (shown in percentage) in normal PBMC and two 
cancer cell lines K562 and HL60. Small RNAs belonging to the miRNA family constitute the majority as in normal PBMC (61%) and HL60 (77%) samples. 
However, in K562 miRNAs constitute only 18% of the sRNA population.
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results suggest that sRNA sequencing is a good approach
for studying miRNA* abundance.
Expression patterns of miRNA clusters
miRNAs are often present in gene clusters and it is gener-
ally believed that individual miRNAs are generated from
common polycistronic transcript by post - transcriptional
processing [51,52]. Since the genes in clusters are co-reg-
ulated and co-transcribed it is expected that the levels of
these miRNAs are likely to be similar. This was investi-
gated by checking the relative levels of individual miR-
NAs present in clusters using the expression patterns
derived from deep sequencing. A total of 265 miRNA
genes organized in 68 clusters were studied. As the
sequencing reads represent mainly mature miRNAs and
not individual precursors, it was not possible to analyze
some of the clusters, such as those containing miR-15a,
16-1 and 15b, 16-2 that encode different precursors but
the same mature miRNA. Furthermore, 19 clusters were
also excluded from analysis as the miRNAs encoded in
these clusters were either not expressed or expressed
below 1 TPM based on our data. Therefore in this study
results from analysis of only 20 clusters are shown (Addi-
tional file 2).
The level of expression of different miRNAs in many
clusters displayed variable expression as exemplified by
the cluster containing miR-532 and 99b (Figure 5). In
some cases the variation observed within a cluster was as
much as 500 fold and the miRNA that showed highest
level of expression was not the one closest to the tran-
scription start site. For example, miR-25 showed highest
expression though it was farthest from the start site in
miR-106b cluster (Figure 5). This is likely to be due to
variation in processing mechanisms at post - transcrip-
tional level as has been seen in case of p53-mediated
alteration in processing some of the miRNAs, such as
miR-16-1 [53]. Overall the results suggest that the levels
of miRNAs in any cell may be regulated by a number of
different processes and mechanistic details of many of
these are not yet known.
Differentially Regulated miRNAs in K562 and HL60
Microarray based methods have been used extensively to
profile expression levels of annotated genes at genomic
scale. These methods cannot be used satisfactorily for
analyzing expression levels of unknown transcripts. Deep
sequencing of cellular RNAs is an alternative approach
for deciphering expression profiles of genes [46,54].
Though a few reports describing analysis of differentially
expressed miRNAs deciphered by deep sequencing are
available, there is no study yet on human PBMC. More-
over, there is no standardized tool available for profiling
miRNA expression using deep sequencing of sRNA
[47,55]. Therefore we have studied normal peripheral
blood mononuclear cells from two different individuals
and cancer cells of myeloid lineage, K562 (chronic myelo-
cytic leukemia) and HL60 (acute promyelocytic leuke-
mia) by deep sequencing of sRNAs followed by analysis of
the sequences using a custom designed computation
pipeline. We used intersection of two methods for finding
differentially expressed genes; a) SAM (significance anal-
ysis of microarrays) that allows for the control of false
detection rate (FDR) and b) fold change, that is, miRNAs
that showed more than 2.5 fold differences when com-
pared to both normal samples. A list of differentially reg-
ulated miRNAs is shown (Figure 6). Interestingly, miR-1,
101, 106b, 146b-5p, 151-3p, 192, 21, 22, 27b, 30e and 361-
3p displayed low expression in both the cell lines indicat-
ing a common role in leukemia genesis or progression
(Figure 6, see inset). In K562 most of the miRNAs were
down regulated except miR-486-3p and miR-504. The
expression patterns derived from sRNA sequences were
Figure 3 Overall level of expression of known miRNAs. The distri-
bution of known miRNA levels with respect to number of miRNAs is 
shown. Numbers of sequence reads are taken as miRNA levels and the 
values are represented in the form of range of values. The expression 
levels of the miRNAs span up to five orders of magnitude.
Figure 4 The abundance of selected miRNAs in human normal 
PBMC. The numbers of reads were used as expression level of respec-
tive miRNAs. [A]. Some of the highly expressing miRNAs (> 10,000 
counts). [B]. Some of the low expressing miRNAs (< 10 counts).
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Figure 5 Differential expression of individual miRNAs present in the same cluster in different datasets. Here TPM (transcript per million) is 
used as a measure of expression. [A] miRNAs belonging to cluster miR-532, [B] cluster miR-99b and [C] cluster miR-106b in normal PBMC, K562 and 
HL60 cell lines. A large variation in expression levels of different miRNAs present within the same cluster is observed.
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both qualitative and quantitative analysis of RNA levels
[25,56]. Down regulation of expression of some of the
miRNAs, such as miR-16, 22, 27a, 192 and let-7g in CML
cell line K562 was observed using RPA assay (Figure 7).
RNU6B was used as a loading control, for all the samples.
We have also used quantitative RT-PCR for validating
some of the results derived by deep sequencing and RPA.
Fold differences in the expression of some of the differen-
tially expressed genes in normal and K562 cells (miR-22
and miR-27a) using all three methods were found to be
comparable indicating quantitative nature of these
approaches (Additional file 3).
While miR-21 was found to be one of the down regu-
lated miRNAs in our study, it is expressed at high level in
all the cancers tested till date indicating that miRNA
expression is likely to be cell type and context dependent
[18]. Reduced expression of some of the miRNAs, such as
miR-16, 151 and 142 was previously reported in CML
[57-59]. Up regulation of the polycistronic miR-17-92
cluster in CD34+ cells of CML patients was initially
described by Venturini et al., 2007 and later was chal-
lenged by Agirre et al., 2008 [59,60]. According to the lat-
ter group there is no significant increase in the expression
of this cluster in CML cells. We too did not observe any
induction of this cluster in K562 cell line in agreement
with the latter group.
A significant number of differentially expressed miR-
NAs of HL60 (downregulated-miR-101, 126, 27b, 7; up
regulated- let-7a, let-7d, miR-181a, -181a*, -181b and
miR-199b) were mapped to chromosome 9 (Figure 8).
Differential expression of miR-181a family (miR-181a,
181a* and 181b) was previously reported [61]. Some of
the differentially regulated miRNAs of K562, such as
Figure 6 Differentially regulated known miRNAs. Up regulated/down regulated miRNAs are represented in the form of Venn diagrams. A subset 
of miRNAs that are differentially regulated but common in both cell lines as compared to normal PBMC is in the overlapped area and their expression 
levels can be seen in the heat map. Heat map of some of the differentially regulated known miRNAs with respect to datasets from normal PBMC and 
cancer cell lines K562 and HL60 is shown as an inset.
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chromosome 9. The genomic locations of some of these
miRNAs were distant from the ABL gene locus. Altera-
tions in chromosome 9 are associated with a large num-
ber of diseases, particularly cancer [62]. Therefore, there
may be a link between alterations in chromosome 9 and
differential expression of miRNAs.
Predicted targets of differentially regulated miRNAs
Identification of putative targets may help to understand
the biological role of the differentially regulated miRNAs.
In this study two different approaches were used for tar-
get identification. In the first approach a number of dif-
ferent software tools were employed for target prediction
and in the second approach mRNA expression profiles
were generated and the genes that showed inverse corre-
lation with miRNA expression were identified. The sec-
ond approach is based on a number of observations
where target mRNA degradation by miRNAs were
reported [63,64]. For computational prediction stringent
criteria, that is, only those genes that are predicted to be
target of specific miRNAs by at least five of the eleven
established target prediction programs (DIANA-microT,
MicroInspector, miRanda, MirTarget2, miTarget,
NBmiRTar, PicTar, PITA, RNA22, RNAhybrid, and Tar-
getScan/TargertScanS) integrated by miRecords and also
showed expression levels that are inversely correlated
with the specific miRNA levels were considered [65].
Putative targets of differentially regulated miRNAs are
shown in Additional file 4 (K562) and Additional file 5
(HL60). Genes targeted by three or more miRNAs are
shown in Table 1. Genes that are targets of multiple miR-
NAs are likely to be tightly regulated and may show
graded response on the basis of expression of different
miRNAs [66]. MEIS2, up regulated in K562, was found to
be the target of up to five different miRNAs, down regu-
lated in both K562 and HL60. MEIS2 has been previously
reported to be important for myeloid leukemogenesis
[67]. Similarly, SMAD7 a down regulated gene in HL60 is
predicted to be a target of three miRNAs, up regulated in
HL60. It is known that SMAD7 regulates SMAD and
mitogen activated kinase (MAPKs) signaling and controls
erythroid and megakaryocytic differentiation of erythro-
leukemia cells [68]. TRIB2, multiply targeted by three up
regulated miRNAs in HL60 has been reported to be pres-
ent at low levels in AML [69].
Expression of intronic miRNAs
Many intron-encoded miRNAs are processed in
DROSHA independent way (miRtrons) [70]. We have
also analysed expression levels of differentially regulated
intronic miRNAs. In order to check if differential expres-
sion of intronic miRNAs is due to transcriptional or post
- transcriptional mechanisms, the levels of intronic miR-
NAs were compared with that of the host transcripts.
Comparative analysis revealed positive correlations with
respect to 8 out of 14 intronic miRNA - mRNA pairs
(Table 2). Unlike miRNAs in clusters, the expression of
Figure 7 Expression levels of some of the known miRNAs deter-
mined by RNase protection assay. The relative expression levels of 
some of the differentially regulated miRNAs were determined using 
RPA. Briefly, total RNA from indicated cells was incubated with a la-
belled probe specific for a given miRNA and eventually treated with ri-
bonuclease as described in the "Methods". The protected fragments, 
suggesting presence of specific transcripts, were first separated on 
12% urea PAGE and then visualized by phosphorimager. Loading con-
trol was transcripts corresponding to RNU6B visualized using RPA.
Figure 8 A map of chromosome 9 showing locations of the differ-
entially expressed HL60 miRNAs. The differentially expressed HL60 
miRNAs were mapped to chromosomes based on the coordinates 
(GRCh37) available on miRBase version 14. The chromosome 9 is 
shown here as most of the miRNAs mapped to this chromosome.
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Table 1: List of Genes targeted by 3 or more differentially regulated miRNAs in K562 and HL60.
Genes targeted by 3 or more downregulated 
miRNAs in K562
Genes targeted by 3 or more 
downregulated miRNAs in HL60
Genes targeted by 3 or more upregulated 
miRNAs in HL60
ABCC5 let-7g, let-7i, miR-101 BCL11A miR-1, miR-21, miR-152 ARID3B let-7a, let-7c, let-7d, miR-98
ACVR2B miR-16, miR-101, miR-186, EDEM3 miR-27b, miR-30e, miR-101 ARRDC3 miR-25, miR-181a, miR-181b
ADAMTS3 miR-16, miR-30e, miR-146b-5p GALNT7 miR-7, miR-27b, miR-30e BAZ2A miR-25, miR-99a, miR-181a
ARRDC4 miR-27a, miR-27b, let-7i, let-7g MEIS2 miR-27b, miR-30e, miR-101, 
miR-194
CCR7 let-7a, let-7b, let-7c, let-7d
BZW2 let-7g, let-7i, miR-101 PHF6 miR-1, miR-30e, miR-101, 
miR-106b
CD200R1 let-7a, let-7b, let-7c, let-7d, miR-98
CDC25A let-7g, let-7i, miR-16, miR-21, 
miR-339-3p
PTGFRN miR-30e, miR-106b, miR-
146b-5p
CPEB2 let-7a, let-7b, let-7c, let-7d, miR-25, 
miR-98
CIT miR-27a, miR-27b, miR-30e, 
miR-142-5p
SATB2 miR-22, miR-27b, miR-30e CPEB4 miR-25, miR-181a, miR-181b
CLCN3 miR-1, miR-101, miR-27a, miR-
27b
DUSP16 let-7a, let-7b, let-7c, miR-98
CLDN12 let-7g, let-7i, miR-16 EGR3 let-7a, let-7b, let-7c, let-7d, miR-98, 
miR-181a
CPEB1 let-7g, let-7i, miR-1, miR-22 EPHA4 let-7a, let-7b, let-7c, miR-98, miR-
181a
DCBLD2 miR-16, miR-24, miR-101 FOS miR-181a, miR-181b, miR-221
E2F7 miR-16, miR-27a, miR-27b GCNT4 let-7a, let-7b, let-7c, let-7d, miR-98
GALNT7 miR-27a, miR-27b, miR-30e GPX7 let-7a, let-7b, let-7c
HIC2 let-7g, let-7i, miR-24, miR-30e, 
miR-146b-5p
IGF2BP2 let-7a, let-7b, let-7c, miR-98, 
miR-181a
IGF2BP3 let-7g, let-7i, miR-142-5p ITGB3 let-7a, let-7b, let-7c, miR-98
LIN28B let-7g, let-7i, miR-30e KIAA1539 let-7a, let-7b, let-7c, let-7d, miR-98
MEIS2 let-7i, miR-27a, miR-27b, 
miR-30e, miR-101
KLHL24 let-7a, let-7b, let-7c, miR-98, miR-
618
NEDD4 miR-27a, miR-27b, miR-30e LRIG1 let-7a, let-7b, let-7c, let-7d, miR-98, 
miR-425
PDIK1L miR-1, miR-16, miR-22, miR-142-
5p
MAP3K3 let-7b, miR-181a, miR-181b
PHF6 miR-1, miR-30e, miR-106b, miR-
186
MYO1F let-7a, let-7b, let-7c, let-7d
PTGFRN miR-30e, miR-106, miR-146b-5p PPP1R16B let-7a, let-7b, let-7c, let-7d, miR-98
RELN miR-16, miR-27a, miR-27b PRKCE miR-25, miR-181a, miR-181b
SATB2 miR-16, miR-22, miR-27a, miR-
27b, miR-30e
RAB11FIP4 let-7a, let-7b, let-7c, let-7d, miR-98
SGMS1 miR-27a, miR-27b, miR-106b, 
miR-142-5p
SLAMF6 let-7a, let-7b, let-7c, let-7d, miR-98
SPRED1 miR-1, miR-16, miR-101 SLC30A4 let-7a, let-7b, let-7c, miR-98
STRBP let-7g, let-7i, miR-146b-5p SLC35D2 let-7a, let-7b, let-7c, let-7d, miR-98
WEE 1 miR-16, miR-27a, miR-106b SLC4A4 let-7a, let-7b, let-7c, let-7d
SMAD7 miR-25, miR-181a, miR-181b
SNN let-7a, let-7b, let-7c, let-7d,
miR-25, miR-98, miR-181a
STK40 let-7a, let-7b, let-7c, let-7d,
miR-98
SYT11 let-7a, let-7b, let-7c, let-7d
TMEM2 let-7a, let-7b, let-7c, let-7d
TRIB2 let-7a, let-7b, let-7c, miR-98
UTRN let-7a, let-7b, let-7c, let-7d, miR-98
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controlled.
miRNA Biogenesis Machinery
The analysis of microarray data revealed induction in the
expression of some of the miRNA biogenesis genes
(RNASEN, DGCR8, XPO5, RAN) in K562 cell line (Table
3). However, DICER1 was found to be down regulated
(1.79 fold). This would result in a likely increase in the
pre-miRNA population in cytosol but decrease in accu-
mulation of mature miRNAs. This is consistent with the
observation that K562 cells contain relatively less amount
of miRNAs and that 23 out of 25 differentially expressed
miRNAs are down regulated (see Figure 6). This observa-
tion was not due to artifact as two independent sequenc-
ing of sRNAs from K562 cells gave similar results (data
not shown here). Low DICER and let-7 levels were also
observed in lung adenocarcinoma [20]. In contrast, a
higher level of DICER1 in prostate adenocarcinoma
accounted for up regulation of 39 of 45 differentially
expressed miRNAs [71]. In HL60 some of the compo-
nents of biogenesis machinery (RNASEN and XPO5)
were found to be up regulated.
Identification of Novel MicroRNA genes
In principle deep sequencing of sRNAs should generate
sequences from as yet unannotated regions of the
genome. The analysis of the sequences through computa-
tional pipeline (Figure 9) showed a large number of unan-
notated sequences that are encoded by either intergenic
or intronic regions. Since miRNAs are predominantly
encoded by intergenic and intronic regions, these
sequences were analyzed by a set of computational tools
to identify putative novel miRNAs. Since predictions are
based on identifying miRNA precursors, genomic regions
(70 nucleotides) surrounding the sRNA sequences were
extracted (see "Methods" for details). A total of 370 (357
major + 13 minor) novel miRNAs were predicted using
computational pipeline (Additional file 6). The sequences
and chromosomal locations of the predicted novel miR-
NAs from intronic and intergenic regions are listed in the
supplementary table (Additional files 7 and 8). More than
Table 2: Correlation of expression patterns in A) K562 and B) HL60 cancer lines between differentially regulated intronic 
miRNAs and their host genes.
A) K562
miRNA Host Transcript miRNA:Host transcript Status
miR-342 EVL Downregulated
miR-548e SHOC2 Downregulated
miR-486 ANK1 Upregulated
B) HL60
miRNA Host Transcript miRNA:Host transcript Status
miR-22 C17orf91 Downregulated
miR-151 PTK2 Downregulated
miR-199b DNM1 Upregulated
miR-25 MCM7 Upregulated
miR-618 LIN7A Upregulated
Table 3: Altered levels of miRNA biogenesis and miRISC components in K562 and HL60.
Protein Function K562/Normal
(Fold Change)
HL60/Normal
(Fold Change)
DROSHA (RNASEN) PrimiRNA processing 2.238954 2.017825
DGCR8 PrimiRNA processing 2.078018 Unchanged
XPO5 Exporting premiRNA 2.669646 2.199101
RAN Exporting premiRNA 1.832214 Unchanged
DICER1 PremiRNA processing -1.79971 Unchanged
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lower than 10. Many novel miRNAs in our dataset
showed presence of 1-11 isomiRs with varying frequen-
cies. For example, frequencies ranging from 1-280 were
observed for eight isomiRs of jnuhsa-204. Presence of
isomiRs certainly strengthens classification of these mol-
ecules as novel miRNAs [47]. These datasets were also
analyzed using miRDeep, a published tool for miRNA
analysis of deep sequencing data [48]. The number of
novel miRNAs predicted by miRDeep is much less than
that using the pipeline described here (Additional files 7
and 8). This may be due to stringent criteria used by
miRDeep that quite often misses known miRNAs. The
expression of a few novel miRNAs, missed by miRDeep
but predicted by "in-house tools", was validated through
real-time PCR (for precursor miRNA) or RNase protec-
tion assay (for mature miRNAs) as shown in Figure 10
and 11. Interestingly miRNAs that were present as single-
ton (for example- jnuhsa-4-3p, jnuhsa-93-3p) were also
detected using RNase protection assay (Figure 11). We
also mapped predicted novel miRNAs to clusters based
on the inter-miRNA distance of less than 20 kb (Figure
12). Some of the clusters contained only novel miRNAs
while many others were part of previously known clusters
[72]. Based on miRDeep prediction a total of 12 novel
miRNAs showed similarity in the seed region with the
known miRNAs indicating that these miRNAs are likely
to belong to the same family and thus may share common
biology (Additional files 7 and 8).
Discussion
Our effort to understand the microRNAome of human
leukocytes through deep sequencing technology has
given us several interesting observations. These include
discovery of novel miRNAs and a valuable list of differen-
tially expressed miRNAs in chronic and acute myeloge-
nous leukemia. The diversity in the miRNA wealth was
realized through the detection of large number of novel
miRNAs. Our major findings are a list of expressed miR-
NAs (534 known and 370 novel) in leukocytes and the
discovery that the expression of miRNAs may be con-
trolled by regulating post - transcriptional events, such as
manipulating the level of DICER, an enzyme involved in
biosynthesis of miRNAs in tumor cells (K562). Generally,
singletons in the sequenced samples are not taken into
consideration, as these are likely to occur due to potential
sequencing error or transcription noise [73]. Our experi-
mental results show convincingly that such miRNAs are
likely to be real and not a result of artifact of sequencing.
The known miRNAs found to be most abundant in all
the four samples were members of the let-7 family, 103,
185 and 320a, which were also reported in peripheral
blood mononuclear cells using "Taqman microRNA
assay" [50]. Therefore our results are in agreement with
previous studies based on a different methodology. There
are multiple mechanisms that are likely to regulate
miRNA levels similar to that of mRNAs. These include
Figure 10 Detection of precursor novel miRNAs through Real-
time PCR. Real-time PCR confirmation of the precursors of novel miR-
NAs predicted through CID, CSHMM, MiPred tools. A no-RT-PCR reac-
tion is used as negative control.
Figure 9 Flowchart describing the computational pipeline used 
for prediction of novel miRNAs. The sequencing reads that did not 
match with any of the databases of elimination pipeline, but matched 
with the human intergenic and intronic sequences, were extracted 
along with flanking sequences from human genome. These were then 
analysed by a number of miRNA precursor prediction algorithms and 
the hits were further analysed by a set of filters as described. The final 
output of the pipeline gives a list of novel miRNAs.
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It is generally believed that levels of miRNAs are regu-
lated transcriptionally [74,75]. In this study an attempt
was made to understand the role of different mechanisms
in controlling miRNA levels by studying levels of individ-
ual miRNAs present in clusters and intronic miRNAs. It
is expected that all miRNAs in a cluster belong to one
transcription unit and are supposed to be synthesized as
one long precursor [51,52]. Since many miRNAs of a
cluster showed variable expression patterns it is likely
that the levels are controlled using post - transcriptional
mechanisms. Therefore, regulation of post - transcrip-
tional processing may be a preferred mechanism, instead
of transcription control in case of miRNAs present in
clusters. Studies describing the role of post - transcrip-
tional mechanism in regulating levels of a number of
miRNAs have been recently published [53,76]. On the
other hand our results regarding relative levels of intronic
miRNA and the host mRNAs do indicate that the levels of
many intronic miRNAs are regulated at transcriptional
level.
The isomiRs of different miRNAs were also frequently
found suggesting that these do not arise due to rare
events. As 5' and 3' ends of mature miRNAs are defined
by processing from DROSHA and DICER, respectively, it
is likely that isomiRs with extra nucleotides at the 5' end
comes from variation in DROSHA processing while with
extra bases at the 3' end comes from variation in DICER
processing. Another possibility is processing of mature
miRNA ends by yet an unidentified end-processing
enzyme in the nucleus. Whether the extra nucleotides of
Figure 11 Predicted novel miRNAs. A. A partial list of novel miRNAs predicted from deep sequencing data is displayed along with chromosomal 
location and the scores from different prediction tools. B. The precursor sequence and the secondary structure of the novel miRNAs. The highlighted 
regions in blue and yellow colour indicate the presence of 5p and 3p mature miRNA sequences, respectively. Note that the sequenced mature puta-
tive miRNAs map to the stem part of the structure. C. The expressions of these miRNAs were independently validated by RPA. RPA was carried out as 
described in the legend for Figure 7 using total RNA from normal PBMC and K562 cell lines. The phosphor imager images are shown. RNU6B transcripts 
were used as a control. Some of the miRNA star sequences were also detected. The brightness/contrast have been changed to normalize the signals 
across different probes.
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ated.
A number of differentially expressed miRNAs and their
potential targets were identified by comparing miRNA
and mRNA levels of normal PBMC versus that of two
myeloid cancer cell lines K562 and HL60 along with com-
putation approach. This strategy was used as degradation
of many mRNAs was observed as a result of miRNA
action [77]. Both K562 and HL60 have been used as refer-
ence cell lines for studying the cellular and molecular
events involved in the proliferation and differentiation of
chronic myeloid or acute promyelocytic leukemia,
respectively. Many miRNAs that were previously
reported to be involved as tumor suppressors, such as let-
7 g, miR-101, 16 and 192 were found to be down regu-
lated in the leukemia cell lines. Many of the differentially
regulated miRNAs, identified in this study have been
reported to be involved in various cellular processes like
cell cycle (miR-192) [78], apoptosis (miR-16, -126, -98)
[21,79,80] differentiation (miR-27a, -181, -342, -223)
[28,81-83] DNA repair (miR-24, -210) [84,85] metastasis
[86], erythroid maturation (miR-22) [87], erythropoiesis
(miR-24) [88] and hematopoiesis (miR-142, -181) [89,90];
highlighting their putative role in leukemogenesis or pro-
gression. Strikingly, majority of the differentially regu-
lated miRNAs were found to be down regulated in K562
cell line. It is possible that low level of DICER, as revealed
by gene expression profiling, is responsible for an overall
reduction in the miRNA population. Global down regula-
tion of miRNAs in mouse T cells using PCR and conven-
tional sequencing approach was reported before [91].
However, the cause of the down regulation was not clear,
as mRNA profiling was not carried out. DICER has also
been implicated in mouse T cell functions [92]. Our stud-
ies strongly suggest that there may be a link between
DICER and miRNA levels. Many of the genes, identified
in this study as the potential targets of differentially regu-
lated miRNAs are known to be involved in cancer
through their effects on cell differentiation (CDK6, LIFR),
apoptosis (PIM1) or hematopoiesis (GATA2, TAL1) [93-
97]. Interestingly, majority of the targets of the cancer-
associated miRNAs, such as -ARHGEF, CDK6, ETV5,
GATA2, PIM1, LIFR, TAL1, PPARG, RANBP17, TFRC
FOXP1 LPP, NCOA2 and NR4A3 have been previously
shown to be associated with leukemogenesis.
One of the features of this study is the computation
pipeline that identifies novel miRNAs among sRNA
sequences. This pipeline is different from other available
pipelines as it has custom designed tools for identifica-
tion of novel miRNAs that involve pre-processing of the
Figure 12 Clustering of the novel miRNAs. A. Novel miRNAs occurring in the vicinity of the known miRNAs. B. Novel miRNAs forming a new cluster.
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and filtering to get novel predictions. The evidences sup-
porting the predictions are identification of potential pre-
cursors by specific precursor identification tools,
presence of star sequences, presence of isomiRs and in
some cases experimental validation. The fact that even a
single sequence read may not be a noise or error, has been
validated by observing corresponding sRNA experimen-
tally and indicates the power of our computation pipeline
in identification of novel miRNAs. The total number of
novel miRNAs identified from all the four samples is 370.
Therefore, total number of miRNAs encoded by the
human genome may be much larger than current esti-
mate [98].
Conclusions
In conclusion we list about 904 miRNAs that are
expressed in normal and cancerous leukocytes, nearly
41% of these are novel. Our analysis shows that some of
the novel miRNAs are likely to be clustered in the
genome similar to many known clusters of miRNAs.
Moreover, we have also identified a number of miRNAs
that are differentially expressed in cancer cells studied by
us. These are likely to be new markers/cause of carcino-
genesis. In addition we show that miRNA levels can be
regulated at post - transcriptional processing stage. Our
results also show that singletons in deep sequencing
reads are unlikely to be sequencing artifacts. In K562 cells
low levels of miRNAs is correlated with reduced level of
the enzyme DICER. In addition we have developed an
improved automated computation pipeline for analysis of
deep sequencing data to obtain quantitative profiles of
known and novel miRNAs. Based on our observations, it
is now possible to generate leukocyte specific miRNA
arrays in order to study expression profiles of all miRNAs
relevant to leukocytes. Similar approach can be used to
generate other tissue specific miRNAome.
Methods
Cell lines and blood samples
The human chronic myeloid leukemia blast crisis cell
line, K562 and acute promyelocytic leukemia cell line,
HL60 were obtained from National Centre for Cell Sci-
ences, Pune and maintained in RPMI 1640 and DMEM
(Gibco) medium, respectively. The medium was supple-
mented with 10% FBS and penicillin-streptomycin and
maintained at 37°C with 5% CO2 in incubator chamber.
Buffy coat of healthy blood donors (N1 and N2) were col-
lected from volunteers. Red cell lysis buffer (0.144M
NH4Cl, 0.01M NH4HCO3) was added to buffy coat to lyse
the remnant RBCs and pure WBC population was
obtained by centrifugation at 3000 g.
RNA Isolation and sequencing
Total RNA isolation was carried out from peripheral
blood and cell lines using TRIzol® Reagent (Invitrogen) as
per manufacturer's instruction. RNA preparations were
stored at - 80-°C till further use. Small RNA (sRNA) pop-
ulation was isolated by separating 10 μg of total RNA on
denaturing polyacrylamide gel electrophoresis (PAGE)
and cutting a portion of the gel corresponding to the size
18-30 nucleotides based standard oligonucleotide mark-
ers. Adapter (5') was ligated to sRNA population and
ligated RNAs (40-60 nt) were purified by running on urea
PAGE. This was followed by 3' adapter ligation and puri-
fication of adapter ligated RNAs (70-90 nt) in a similar
manner. Modified sRNAs were reverse transcribed and
then PCR amplified with adapter specific primers and the
amplified cDNAs were finally purified on Urea PAGE to
generate cDNA tag libraries for sequencing by illumina
genome analyzer. The average number of sequencing
reads was around 4.9 million.
Datasets
Four sRNA sequencing data comprising of peripheral
blood leukocytes of two normal individuals (N1, N2) and
tumor cells K562 and HL60 were obtained from Illumina
fast track sequencing services. For each sample a
Sequence file and a Tag file was provided. The Tag file
comprises of unique sequences with their corresponding
frequency. Tag Files are generated post alignment as a
summary of Sequence Files and every Sequence File has a
corresponding Tag File. Tag Files are generated to give the
researcher an indication of most common to most rare
sequences in the dataset. The numerical frequency of
each sequence in the Sequence File for gene expression
gives a true indication of relative expression of sequence
transcripts. The unique sequences in the Tag files contain
a 3' adaptor sequence (TCGTATGCCGTCTTCT-
GCTTG). The amount of the 3' adapter is variable and is
dependent on the length of the sRNA. Each delivered
sequence is 33/35 bases in length. A part of the adaptor
sequence is seen in each sequence if the sRNA is shorter
than 33/35 bases. This adapter and segments of it needs
to be trimmed for proper alignment to the transcrip-
tome/genome.
Preparation/Processing of the datasets
i). Removal of the adaptor sequences: Since the
sequence of the adaptor is known, a perl script was writ-
ten to trim the adaptors.
ii). Clustering and removal of redundancy after
removal of the adaptor sequence: Although the tag file
contained unique sequences, there were some, which
after the removal of the adaptor were redundant. These
identical sequences were represented once and their fre-
quency was summed up.
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Page 14 of 18iii). Sequences less than 10 nucleotides in length were
excluded
iv). Conversion into fasta format: The final trimmed
file was then converted into fasta format where the
unique header (sequence identity) retained the informa-
tion of the sequences length and frequency. The sequence
ID comprised of a running number along with the length
and frequency of that sequence.
Small RNA annotation
The sRNA sequences obtained were annotated against
the known databases using the following protocol-
i). Known/annotated sequence databases
List of the databases used for the annotation/elimination
pipeline were:
a) Mature miRNAs: from miRNA registry, release 14
(includes a total of 904 miRNAs [718 mature (major)
+186 stars (minors)].
b) ncRNAs: from Ensembl
"Homo_sapiens.NCBI36.56.ncrna.fa" (includes the
precursor miRNAs and other ncRNAs like sn/sno/sca
RNAs, tRNAs, rRNAs).
c) RNA database from the FTP site NCBI (includes
rRNAs and mRNAs).
d) The exons were obtained from the Contig files by a
self written script.
e) Intergenic/intronic sequences: obtained through
in-house built Perl script (using the Homo Sapiens
Contig file 29 Feb, 2008 version). These sequences
served as a source for finding novel miRNAs (inter-
genic/intronic).
ii). Finding Known miRNAs
One of our objectives was to study the expression pattern
of the known miRNAs. To generate the expression profile
of the known miRNAs, the sRNA sequences of all the 4
samples were matched against the known miRNA
sequences using BLASTN and an in house built pattern
matching tool. The parameters used for BLAST were
tuned to obtain maximum matches, such as the word size
was set to 7 nucleotides, filtering was turned off and the
number of alignments reported were increased.
iii). The Elimination Pipeline
An in house - built script was written to do a fast match-
ing of the sequences with the created databases. A mis-
match of up to 2 nucleotides was allowed. The pool of
unmatched sequences at the end of the pipeline served as
a source of novel miRNAs (Figure 1).
Normalisation of the data/Calculation of Transcripts Parts 
Per Million (TPM)
Normalisation was carried out as the total number of
reads from different experiments was not same and varia-
tions in the number of reads of individual miRNA can be
due to sequencing depth. The number of reads of a tran-
script/sequence (representing a known miRNA) was
divided by the total clone count of the sample and multi-
plied by 106. The total clone count is the sum of the fre-
quencies of all the unique sequences/transcripts present
in the trimmed file. The Additional file 1 contains a list of
the known miRNAs found in all the 4 samples along with
their respective frequencies and TPM values.
Selecting Differentially expressed MicroRNAs
Differentially expressed miRNAs were identified by using
a combination of two methods:
i) SAM Analysis
We performed the t-test procedure within significance
analysis of microarrays (SAM) to look for differentially
expressed miRNAs. SAM calculates a score for each gene
on the basis of the change in expression relative to the
standard deviation of all measurements.
ii) Fold Change
The known miRNAs in normal samples were compared
to the cancer cell line. The miRNAs showing more than
2.5 fold difference as compared to both the normal cells
were considered as differentially regulated. The samples
with less than 10 TPM in both normal and cancer sam-
ples were ignored.
Novel miRNA Prediction
The strategy is based on first removing all known RNAs
including those derived from exonic regions and then
identifying those that are derived from intronic and inter-
genic regions. These were then subjected to some of the
ab initio miRNA prediction algorithms like SCFG based
CID-miRNA [99] and CSHMM [100] that use stringent
criteria to distinguish between real and pseudo miRNAs.
Besides this we ensure high discriminative power by
using the following filters:
a) Occurrence of the sequence in the stem region of
the precursor
b) Presence of IsomiRs
c) Presence of minor/star sequences.
d) Taking a consensus among the prediction tools
Following is the detailed pipeline used for the predic-
tion of novel miRNAs:
i) Extraction of matches from the intergenic/intronic regions 
of the human genome
The unmatched sequences (from the elimination pipe-
line) were matched to the intergenic/intronic regions.
The exact matched sequences were extracted along with
70 nucleotides flanking both the ends representing
potential precursor sequences.
ii). Folding the extended sequences and checking its location 
in the folded structure
The sequences were scanned for presence of potential
precursor miRNA using CID-miRNA [99] and CSHMM
[100] prediction tools. The folded sequences generated
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miRNA obtained by sequencing) occurs in the folded
putative precursor as the window scanning approach
used could report a folded structure not involving the
concerned sRNA. Only those hairpins were kept which
contained sRNA. The next step involved locating the
position of the sRNA in the hairpins. Since mature miR-
NAs are known to be arising from the stem portion and
not the loop, only those hairpins in which the sRNAs
occurred in the stem were classified as correct cases and
the remaining as prediction errors. These correct cases
were further tested by MiPred [101].
iii). Finding IsomiRs and Star sequences
A list of all the predicted correct precursor sequences was
created and the sRNAs derived from common precursors
were grouped into a common family. The sRNAs derived
from the same precursors were kept together in a family.
The most abundant member was designated as the
mature miRNA. The sRNAs that differed from the repre-
sentative by a few nucleotides were called IsomiRs and
those that had a different, partially complementary
sequence and were located in the other strand (stem of
the hairpin loop) were called stars. The Additional files 7
and 8 comprise of the novel miRNAs grouped into fami-
lies on the basis of sRNAs falling within the same precur-
sor. The representative sequence was chosen on the basis
of abundance. The most abundant sequence was selected
as representative of the family. The scores from the 4
tools (CID-miRNA, CSHMM, miRDeep, MiPred
assigned to the corresponding precursors are also listed).
iv). Locating the potential - novel miRNA in the genome
On the basis of the positions of the predicted novel miR-
NAs, their tendency to occur in a known cluster or a new
cluster was checked. miRNAs located within 20 kb of the
known or novel miRNA were considered as part of the
same cluster.
v). Removal of the redundant miRNAs to get the final list of 
novel miRNAs
The novel miRNAs from the 4 samples (both intergenic
and intronic) were pooled and the redundancy was
removed to get a final set of novel miRNAs. These were
given a unique name (Additional file 6). The representa-
tive miRNAs in the Additional files 7 and 8 along with
their sample IDs also have these names.
RNAse Protection Assay (RPA) for detection of mature 
miRNA and real time RT-PCR for precursor miRNA detection
The RPA assay for mature miRNA detection was done
using mirVana ™ miRNA detection kit as per supplier's
instructions (Applied Biosystems). To detect the precur-
sor miRNA, total RNA was treated with DNAase I (MBI
fermentas). Reverse transcription was done using super-
script® III (Invitrogen) reverse transcriptase as per sup-
plier's instructions. A list of primers used for real time
RT-PCR amplification of precursors of novel miRNAs is
given in Additional file 9. Real-time PCR was done with
following parameters- Initial denaturation - 94°c for 2
min, denaturation- 94°c for 30 sec, annealing- 60°c for 1
min for 40 cycles using SYBR Green PCR Master Mix
(Applied biosystems).
Microarray analysis
Total RNA from normal PBMC and two myeloid leuke-
mia cancer samples (K562 and HL60) was sent for gene
expression profiling using Ocimum microarray platform
(Ocimum, Hyderabad, India). The expression data for
each sample was generated on Affymetrix Human Gene
1.0 ST arrays. A fold change cut-off of ± 1.5 resulted into
FDR < 0.001 for both the comparisons. The quality con-
trol analysis was carried out using Affymetrix Expression
Console (EC). The statistical analysis was performed
using R-programming language and the biological analy-
sis was carried out using GenowizTM software. The data
obtained was normalized and genes showing more than
1.5 fold differences in the cancer cell lines as compared to
normal were marked as differentially expressed genes. A
total of 1856 genes were found to be up regulated and
1696 were down regulated in K562. In HL60, 1497 genes
were up regulated and 1213 genes were found as down-
regulated (Additional file 10).
miRNA target prediction
The most probable targets of the differentially regulated
miRNAs were fished out using following two criteria - 1.
Prediction by at least five of the established target predic-
tion programs- A list of putative targets was prepared
(List A) using intersection between at least five of the
eleven established target prediction programs compiled
by mIRecords: (DIANA-microT, MicroInspector,
miRanda, MirTarget2, miTarget, NBmiRTar, PicTar,
PITA, RNA22, RNAhybrid, and TargetScan/Targ-
ertScanS). 2. Inverse correlation in expression pattern
between miRNA and coding genes- The putative target
genes in list A was compared to the list of differentially
regulated genes (showing more than 1.5 fold difference)
(List B) in K562 and HL60 as obtained from expression
profiling data, and only those genes that show inverse
correlation to the miRNA levels were considered as most
genuine putative targets of the select miRNAs.
Availability and Requirements
The entire computational pipeline described in this paper
is available at the website: http://mirna.jnu.ac.in/
deep_sequencing/deep_sequencing.html. The software is
also available on request.
Accession numbers
The data discussed in this publication have been depos-
ited in NCBI's Gene Expression Omnibus and are accessi-
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Page 16 of 18ble through GEO Series accession number GSE19833
Super series: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE19833
The GSE19833 Super series comprises of the following
sub series:
Microarray Expression data: GSE 19789 (consists of raw
data and normalized data) Deep sequencing data: GSE
19812 sequence data (consists of the raw sequences,
untrimmed tag and trimmed tag files and the expression
profile of the known miRNAs (Additional File 1).
Additional material
Abbreviations
miRNA: microRNA; UTR: untranslated region; RISC: RNA induced silencing com-
plex; PTEN: phosphatase and tensin homolog; RAS: rat sarcoma viral oncogene
homolog; HMGA2: high mobility group AT-hook 2; BCL2: B-cell CLL/lymphoma
2; PBMC: peripheral blood mononuclear cell; SAM: significance analysis of
microarrays; FDR: false discovery rate; CML: chronic myelogenous leukemia;
AML: myelogenous leukemia; ABL: c-abl oncogene 1, receptor tyrosine kinase;
MEIS2: Meis homeobox 2; SMAD7: SMAD family member 7; TRIB2: tribbles
homolog 2 (Drosophila); MAPK: mitogen activated protein kinase; BCL11A: B-
cell CLL/lymphoma 11A (zinc finger protein); ETV4: ets variant 4; IDH1: isoci-
trate dehydrogenase 1 (NADP+), soluble; PPARG: peroxisome proliferator-acti-
vated receptor gamma; EIF4A2: eukaryotic translation initiation factor 4A,
isoform 2; LCK: lymphocyte-specific protein tyrosine kinase; NCOA2: nuclear
receptor coactivator 2; NR4A3: nuclear receptor subfamily 4, group A, member
3; PIM1: proviral integration site 1; RNASEN: ribonuclease type III, nuclear;
DGCR8: DiGeorge syndrome critical region gene 8; XPO5: exportin 5; RAN: ras-
related nuclear protein; PRMT5: protein arginine methyltransferase 5; FXR2:
fragile X mental retardation, autosomal homolog 2; MOV10: Moloney leukemia
virus 10; SNP: single nucleotide polymorphism
Authors' contributions
AB and LK conceptualized the study. CV generated the computational pipeline,
processed, normalized and annotated the data and did the novel miRNA pre-
diction analysis. RK and HMA conducted the miRNA differential expression,
miRNA cluster, microarray data and target prediction analyses and wet experi-
ments. PS provided the RNA samples for sequencing. RG conducted SAM anal-
yses. RK and AB wrote the manuscript. All the authors read and approved the
final manuscript.
Acknowledgements
The authors thank Department of Biotechnology, Government of India for their 
generous support and UPOE-supported HPCF for computing time. RK 
acknowledges support from Department of Science & Technology, GOI for a 
fast track grant. CV acknowledges fellowship from CSIR (CSIR SRF award no: 9/
263/(0772)/9). The authors thank Dr. Narinder Sahni and Prof. Sachin 
Maheswari for helpful discussions. Special thanks to Chetan Aneja who helped 
in constructing the computational pipeline for annotating the data.
Statement - The authors declare no competing financial or other interest in 
relation to this work.
Author Details
1School of Information Technology, Jawaharlal Nehru University, New Delhi, 
India, 2School of Life Sciences, Jawaharlal Nehru University, New Delhi, India 
and 3Department of Medical Oncology, Institute Rotary Cancer Hospital, All 
India Institute of Medical Science, New Delhi, India
References
1. Alvarez-Garcia I, Miska EA: MicroRNA functions in animal development 
and human disease.  Development 2005, 132:4653-4662.
2. Leung AK, Sharp PA: microRNAs: a safeguard against turmoil?  Cell 2007, 
130:581-585.
3. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M: A microRNA component of 
the hypoxic response.  Cell Death Differ 2008, 15:667-671.
4. Spizzo R, Nicoloso MS, Croce CM, Calin GA: SnapShot: MicroRNAs in 
Cancer.  Cell 2009, 137:586-586. e1
5. Ghildiyal M, Zamore PD: Small silencing RNAs: an expanding universe.  
Nat Rev Genet 2009, 10:94-108.
6. Bartel DP: MicroRNAs: target recognition and regulatory functions.  Cell 
2009, 136:215-233.
7. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals.  Nat Rev 
Mol Cell Biol 2009, 10:126-139.
8. Lee Y, Han J, Yeom KH, Jin H, Kim VN: Drosha in primary microRNA 
processing.  Cold Spring Harb Symp Quant Biol 2006, 71:51-57.
9. Tijsterman M, Plasterk RH: Dicers at RISC; the mechanism of RNAi.  Cell 
2004, 117:1-3.
10. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for 
microRNA genomics.  NAR 2008, 36:D154-D158.
11. Rana TM: Illuminating the silence: understanding the structure and 
function of small RNAs.  Nat Rev Mol Cell Biol 2007, 8:23-36.
12. Hammell CM: The microRNA-argonaute complex: a platform for mRNA 
modulation.  RNA Biol 2008, 5:123-127.
13. Ørom UA, Nielsen FC, Lund AH: MicroRNA-10a binds the 5'UTR of 
ribosomal protein mRNAs and enhances their translation.  Mol Cell 
2008, 30:460-471.
14. Barbarotto E, Schmittgen TD, Calin GA: MicroRNAs and cancer: profile, 
profile, profile.  Int J Cancer 2008, 122:969-977.
15. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio 
M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, 
Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression 
signature of human solid tumors defines cancer gene targets.  Proc Natl 
Acad Sci USA 2006, 103:2257-2261.
16. Deng S, Calin GA, Croce CM, Coukos G, Zhang L: Mechanisms of 
microRNA deregulation in human cancer.  Cell Cycle 2008, 7:2643-2646.
Additional file 1 The known miRNAs expression pattern for all the 4 
samples. The known miRNAs found in the 4 samples with their corre-
sponding frequency and TPM values.
Additional file 2 miRNA cluster analysis. Cluster analysis of the known 
miRNAs in Normal1, Normal2, K562 and HL60.
Additional file 3 Comparison of the sensitivity of the three miRNA 
detection methods (Deep sequencing reads, RNase Protection assay 
and quantitative RT-PCR). Fold change differences in normal PBMC versus 
K562 is presented for miR-27a and miR-22 using the three transcript detec-
tion methods.
Additional file 4 List of predicted targets of differentially regulated 
miRNAs showing inverse correlation in microarray data in K562.
Additional file 5 List of predicted targets of differentially regulated 
miRNAs showing inverse correlation in microarray data in HL60.
Additional file 6 List of the predicted 370 novel miRNAs. The precursor 
and mature sequences of the total novel miRNAs are given as text file. 
When the relative abundances clearly indicate which the predominantly 
expressed miRNA is, the mature sequences are assigned names of the form, 
jnuhsa-233 (the predominant product) and jnuhsa-233* (from the opposite 
arm of the precursor). When the data are not sufficient to determine which 
sequence is the predominant one, names like jnuhsa-118-5p (from the 5' 
arm) and jnuhsa-118-3p (from the 3' arm) have been used.
Additional file 7 Details of the intronic novel miRNAs of the 4 sam-
ples. List of the novel miRNAs predicted sample wise, with the information 
on their frequency, isomiRs, chromosomal location and prediction scores 
from CID-miRNA, CSHMM, miRDeep, MiPred.
Additional file 8 Details of the intergenic novel miRNAs of the 4 sam-
ples. List of the novel miRNAs predicted sample wise, with the information 
on their frequency, isomiRs, chromosomal location and prediction scores 
from CID-miRNA, CSHMM, miRDeep, MiPred.
Additional file 9 A list of primers used for amplification of precursors 
of novel miRNAs.
Additional file 10 The normalized expression data along with a list of 
differentially regulated genes (> 1.5 fold) obtained using Ocimum 
microarray platform for K562 and HL60.
Received: 8 September 2009 Accepted: 7 May 2010 
Published: 7 May 2010
This article is available from: http://www.biomedcentral.com/1471-2164/11/288© 2010 Vaz et al; licensee BioMed Central Ltd. is an Open Ac s  article distributed un er th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Ge omics 2010, 11:288
Vaz et al. BMC Genomics 2010, 11:288
http://www.biomedcentral.com/1471-2164/11/288
Page 17 of 1817. Stenvang J, Lindow M, Kauppinen S: Targeting of microRNAs for 
therapeutics.  Biochem Soc Trans 2008, 36:1197-1200.
18. Krichevsky AM, Gabriely G: miR-21: a small multi-faceted RNA.  J Cell Mol 
Med 2009, 13:39-53.
19. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: 
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene 
in human hepatocellular cancer.  Gastroenterology 2007, 133:647-658.
20. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, 
Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T: 
Reduced expression of the let-7 microRNAs in human lung cancers in 
association with shortened postoperative survival.  Cancer Res 2004, 
64:3753-3756.
21. Aqeilan RI, Calin GA, Croce CM: miR-15a and miR-16-1 in cancer: 
discovery, function and future perspectives.  Cell Death Differ 2010, 
17:215-220.
22. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, 
Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 
microRNA family.  Cell 2005, 120:635-647.
23. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the 
HMGA2 oncogene.  Genes Dev 2007, 21:1025-1030.
24. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, 
Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, 
Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting 
BCL2.  Proc Natl Acad Sci USA 2005, 102:13944-13949.
25. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens 
RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: 
Unique microRNA molecular profiles in lung cancer diagnosis and 
prognosis.  Cancer Cell 2006, 9:189-198.
26. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, 
Gleadle JM, Ragoussis J: hsa-miR-210 Is induced by hypoxia and is an 
independent prognostic factor in breast cancer.  Clin Cancer Res 2008, 
14:1340-1348.
27. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch 
DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as 
prognostic marker in advanced ovarian cancer.  Gynecol Oncol 2009, 
114:457-464.
28. Yuan JY, Wang F, Yu J, Yang GH, Liu XL, Zhang JW: MicroRNA-223 
reversibly regulates erythroid and megakaryocytic differentiation of 
K562 cells.  J Cell Mol Med 2009, 13:4551-4559.
29. Chivukula RR, Mendell JT: Abate and switch: miR-145 in stem cell 
differentiation.  Cell 2009, 137:606-608.
30. Hermeking H: The miR-34 family in cancer and apoptosis.  Cell Death 
Differ 2010, 17:193-199.
31. Leucht C, Stigloher C, Wizenmann A, Klafke R, Folchert A, Bally-Cuif L: 
MicroRNA-9 directs late organizer activity of the midbrain-hindbrain 
boundary.  Nat Neurosci 2008, 11:641-648.
32. Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD, McManus MT, 
Baskerville S, Bartel DP, Tabin CJ: The microRNA miR-196 acts upstream 
of Hoxb8 and Shh in limb development.  Nature 2005, 438:671-674.
33. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, 
Greenberg ME: A brain-specific microRNA regulates dendritic spine 
development.  Nature 2006, 439:283-289.
34. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon 
FL, Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal 
muscle proliferation and differentiation.  Nat Genet 2006, 38:228-233.
35. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V: 
Expression profiling of mammalian microRNAs uncovers a subset of 
brain-expressed microRNAs with possible roles in murine and human 
neuronal differentiation.  Genome Biol 2004, 5:R13.
36. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, 
van Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, 
Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T: 
Identification of microRNAs of the herpesvirus family.  Nat Methods 
2005, 2:269-276.
37. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, 
Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-
time quantification of microRNAs by stem-loop RT-PCR.  Nucleic Acids 
Res 2005, 33:e179.
38. Thomson JM, Parker J, Perou CM, Hammond SM: A custom microarray 
platform for analysis of microRNA gene expression.  Nat Methods 2004, 
1:47-53.
39. Beuvink I, KolbF A, Budach W, Garnier A, Lange J, Natt F, Dengler U, Hall J, 
Filipowicz W, Weiler J: A novel microarray approach reveals new tissue-
specific signatures of known and predicted mammalian microRNAs.  
Nucleic Acids Res 2007, 35:e52.
40. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, 
Kim VN: The nuclear RNase III Drosha initiates microRNA processing.  
Nature 2003, 425:415-419.
41. Lu C, Tej SS, Luo S, Haudenschild CD, Meyers BC, Green PJ: Elucidation of 
the small RNA component of the transcriptome.  Science 2005, 
309:1567-1569.
42. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice 
A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, 
Chiaretti S, Foà R, Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, 
Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti 
D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, 
Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, 
Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, 
Zavolan M, Tuschl T: A mammalian microRNA expression atlas based on 
small RNA library sequencing.  Cell 2007, 129:1401-1414.
43. Neely LA, Patel S, Garver J, Gallo M, Hackett M, McLaughlin S, Nadel M, 
Harris J, Gullans S, Rooke J: A single-molecule method for the 
quantitation of microRNA gene expression.  Nat Methods 2006, 3:41-46.
44. Moxon S, Jing R, Szittya G, Schwach F, Rusholme Pilcher RL, Moulton V, 
Dalmay T: Deep sequencing of tomato short RNAs identifies microRNAs 
targeting genes involved in fruit ripening.  Genome Res 2008, 
18:1602-1609.
45. Bar M, Wyman SK, Fritz BR, Qi J, Garg KS, Parkin RK, Kroh EM, Bendoraite A, 
Mitchell PS, Nelson AM, Ruzzo WL, Ware C, Radich JP, Gentleman R, 
Ruohola-Baker H, Tewari M: MicroRNA discovery and profiling in human 
embryonic stem cells by deep sequencing of small RNA libraries.  Stem 
Cells 2008, 26:2496-2505.
46. Glazov EA, Cottee PA, Barris WC, Moore RJ, Dalrymple BP, Tizard ML: A 
microRNA catalog of the developing chicken embryo identified by a 
deep sequencing approach.  Genome Res 2008, 18:957-964.
47. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, 
Zhao Y, McDonald H, Zeng T, Hirst M, Eaves CJ, Marra MA: Application of 
massively parallel sequencing to microRNA profiling and discovery in 
human embryonic stem cells.  Genome Res 2008, 18:610-621.
48. Friedländer MR, Chen W, Adamidi C, Maaskola J, Einspanier R, Knespel S, 
Rajewsky N: Discovering microRNAs from deep sequencing data using 
miRDeep.  Nat Biotechnol 2008, 26:407-415.
49. miRBase: the microRNA database   [http://www.miRBase.org]
50. Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA 
expression profiles in normal human tissues.  BMC Genomics 2007, 
8:166.
51. Altuvia Y, Landgraf P, Lithwick G, Elefant N, Pfeffer S, Aravin A, Brownstein 
MJ, Tuschl T, Margalit H: Clustering and conservation patterns of human 
microRNAs.  Nucleic Acids Res 2005, 33:2697-2706.
52. Yu J, Wang F, Yang GH, Wang FL, Ma YN, Du ZW, Zhang JW: Human 
microRNA clusters: genomic organization and expression profile in 
leukemia cell lines.  Biochem Biophys Res Commun 2006, 349:59-68.
53. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: 
Modulation of microRNA processing by p53.  Nature 2009, 460:529-533.
54. Creighton CJ, Reid JG, Gunaratne PH: Expression profiling of microRNAs 
by deep sequencing.  Brief Bioinform 2009, 10:490-497.
55. 't Hoen PA, Ariyurek Y, Thygesen HH, Vreugdenhil E, Vossen RH, de 
Menezes RX, Boer JM, van Ommen GJ, den Dunnen JT: Deep sequencing-
based expression analysis shows major advances in robustness, 
resolution and inter-lab portability over five microarray platforms.  
Nucleic Acids Res 2008, 36:e141.
56. Ro S, Park C, Young D, Sanders KM, Yan W: Tissue-dependent paired 
expression of miRNAs.  Nucleic Acids Res 2007, 35:5944-5953.
57. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero 
A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub 
TR: MicroRNA expression profiles classify human cancers.  Nature 2005, 
435:834-838.
58. Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP Jr, 
Sloand EM, Kajigaya S, Young NS: Hematopoietic-specific microRNA 
expression in human cells.  Leuk Res 2006, 30:643-647.
59. Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu 
L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-
Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, 
Vaz et al. BMC Genomics 2010, 11:288
http://www.biomedcentral.com/1471-2164/11/288
Page 18 of 18Prósper F: Down-regulation of hsa-miR-10a in chronic myeloid 
leukemia CD34+ cells increases USF2-mediated cell growth.  Mol 
Cancer Res 2008, 6:1830-1840.
60. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, 
Muckenthaler MU, Ganser A, Eder M, Scherr M: Expression of the miR-17-
92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.  Blood 
2007, 109:4399-4405.
61. Merkerova M, Belickova M, Bruchova H: Differential expression of 
microRNAs in hematopoietic cell lineages.  Eur J Haematol 2008, 
81:304-310.
62. Genetics Home Reference   [http://ghr.nlm.nih.gov/chromosome=9]
63. Hausser J, Landthaler M, Jaskiewicz L, Gaidatzis D, Zavolan M: Relative 
contribution of sequence and structure features to the mRNA binding 
of Argonaute/EIF2C-miRNA complexes and the degradation of miRNA 
targets.  Genome Res 2009, 19:2009-2020.
64. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, 
Ferrell JE, Brown PO: Concordant regulation of translation and mRNA 
abundance for hundreds of targets of a human microRNA.  PLoS Biol 
2009, 7:e1000238.
65. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T: miRecords: an integrated 
resource for microRNA-target interactions.  Nucleic Acids Res 
2009:D105-110.
66. Rajewsky N: microRNA target predictions in animals.  Nat Genet 2009, 
38(Suppl):S8-S13.
67. Fujino T, Yamazaki Y, Largaespada DA, Jenkins NA, Copeland NG, 
Hirokawa K, Nakamura T: Inhibition of myeloid differentiation by Hoxa9, 
Hoxb8, and Meis homeobox genes.  Exp Hematol 2001, 29:856-863.
68. Akel S, Bertolette D, Petrow-Sadowski C, Ruscetti FW: Levels of Smad7 
regulate Smad and mitogen activated kinases (MAPKs) signaling and 
controls erythroid and megakaryocytic differentiation of 
erythroleukemia cells.  Platelets 2007, 18:566-578.
69. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, 
Engel JH, Cronk MR, Dorcy KS, McQuary AR, Hockenbery D, Wood B, 
Heimfeld S, Radich JP: Identification of genes with abnormal expression 
changes in acute myeloid leukemia.  Genes Chromosomes Cancer 2008, 
47:8-20.
70. Ruby JG, Jan CH, Bartel DP: Intronic microRNA precursors that bypass 
Drosha processing.  Nature 2007, 448:83-86.
71. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, 
Dhir R: Up-regulation of dicer, a component of the MicroRNA 
machinery, in prostate adenocarcinoma.  Am J Pathol 2006, 
169:1812-1820.
72. Baskerville S, Bartel DP: Microarray profiling of microRNAs reveals 
frequent coexpression with neighboring miRNAs and host genes.  RNA 
2005, 11:241-247.
73. Joshi T, Yan Z, Libault M, Jeong DH, Park S, Green PJ, Sherrier DJ, Farmer A, 
May G, Meyers BC, Xu D, Stacey G: Prediction of novel miRNAs and 
associated target genes in Glycine max.  BMC Bioinformatics 2010, 
11(Suppl 1):S14.
74. Cullen BR: Transcription and processing of human microRNA 
precursors.  Mol Cell 2004, 16:861-865.
75. Johnson SM, Lin SY, Slack FJ: The time of appearance of the C. elegans 
let-7 microRNA is transcriptionally controlled utilizing a temporal 
regulatory element in its promoter.  Dev Biol 2003, 259:364-379.
76. Obernosterer G, Leuschner PJ, Alenius M, Martinez J: Post-transcriptional 
regulation of microRNA expression.  RNA 2006, 12:1161-1167.
77. Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight?  Nat 
Rev Genet 2008, 9:102-114.
78. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, 
Andersen CL, Dobbelstein M: p53-Responsive micrornas 192 and 215 
are capable of inducing cell cycle arrest.  Cancer Res 2008, 
68:10094-10104.
79. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, 
Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, 
Thirman MJ, Golub TR, Rowley JD, Chen J: Distinct microRNA expression 
profiles in acute myeloid leukemia with common translocations.  Proc 
Natl Acad Sci USA 2008, 105:15535-15540.
80. Wang Y, Lee CG: MicroRNA and cancer--focus on apoptosis.  J Cell Mol 
Med 2009, 13:12-23.
81. Schoolmeesters A, Eklund T, Leake D, Vermeulen A, Smith Q, Force Aldred 
S, Fedorov Y: Functional profiling reveals critical role for miRNA in 
differentiation of human mesenchymal stem cells.  PLoS One 2009, 
4:e5605.
82. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, 
Souidi M, Cuvellier S, Harel-Bellan A: The microRNA miR-181 targets the 
homeobox protein Hox-A11 during mammalian myoblast 
differentiation.  Nat Cell Biol 2006, 8:278-284.
83. De Marchis ML, Ballarino M, Salvatori B, Puzzolo MC, Bozzoni I, Fatica A: A 
new molecular network comprising PU.1, interferon regulatory factor 
proteins and miR-342 stimulates ATRA-mediated granulocytic 
differentiation of acute promyelocytic leukemia cells.  Leukemia 2009, 
23:856-862.
84. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, 
Lieberman J, Chowdhury D: miR-24-mediated downregulation of H2AX 
suppresses DNA repair in terminally differentiated blood cells.  Nat 
Struct Mol Biol 2009, 16:492-498.
85. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM: MicroRNA regulation of 
DNA repair gene expression in hypoxic stress.  Cancer Res 2009, 
69:1221-1229.
86. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR: Breast 
cancer metastasis suppressor 1 up-regulates miR-146, which 
suppresses breast cancer metastasis.  Cancer Res 2009, 69:1279-1283.
87. Choong ML, Yang HH, McNiece I: MicroRNA expression profiling during 
human cord blood-derived CD34 cell erythropoiesis.  Exp Hematol 2007, 
35:551-564.
88. Wang Q, Huang Z, Xue H, Jin C, Ju XL, Han JD, Chen YG: MicroRNA miR-24 
inhibits erythropoiesis by targeting activin type I receptor ALK4.  Blood 
2008, 111:588-595.
89. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic 
lineage differentiation.  Science 2004, 303:83-86.
90. Chen CZ, Lodish HF: MicroRNAs as regulators of mammalian 
hematopoiesis.  Semin Immunol 2005, 17:155-165.
91. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, Manjunath N: 
miRNA profiling of naïve, effector and memory CD8 T cells.  PLoS One 
2007, 2:e1020.
92. Cobb BS, Hertweck A, Smith J, O'Connor E, Graf D, Cook T, Smale ST, 
Sakaguchi S, Livesey FJ, Fisher AG, Merkenschlager M: A role for Dicer in 
immune regulation.  J Exp Med 2006, 203:2519-2527.
93. Grossel MJ, Hinds PW: Beyond the cell cycle: a new role for Cdk6 in 
differentiation.  J Cell Biochem 2006, 97:485-493.
94. Aghajanova L, Skottman H, Strömberg AM, Inzunza J, Lahesmaa R, 
Hovatta O: Expression of leukemia inhibitory factor and its receptors is 
increased during differentiation of human embryonic stem cells.  Fertil 
Steril 2006, 86:1193-1209.
95. Andina N, Didichenko S, Schmidt-Mende J, Dahinden CA, Simon HU: 
Proviral integration site for Moloney murine leukemia virus 1, but not 
phosphatidylinositol-3 kinase, is essential in the antiapoptotic 
signaling cascade initiated by IL-5 in eosinophils.  J Allergy Clin Immunol 
2009, 123:603-611.
96. Shimizu R, Yamamoto M: Gene expression regulation and domain 
function of hematopoietic GATA factors.  Semin Cell Dev Biol 2005, 
16:129-136.
97. Hu X, Li X, Valverde K, Fu X, Noguchi C, Qiu Y, Huang S: LSD1-mediated 
epigenetic modification is required for TAL1 function and 
hematopoiesis.  Proc Natl Acad Sci USA 2009, 106:10141-10146.
98. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat 
P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z: Identification of 
hundreds of conserved and nonconserved human microRNAs.  Nature 
Genetics 2005, 37:766-770.
99. Tyagi S, Vaz C, Gupta V, Bhatia R, Maheshwari S, Srinivasan A, Bhattacharya 
A: CID-miRNA: a web server for prediction of novel miRNA precursors 
in human genome.  Biochem Biophys Res Commun 2008, 372:831-834.
100. Agarwal S, Vaz C, Bhattacharya A, Srinivasan A: Prediction of novel 
precursor miRNAs using a context-sensitive hidden Markov Model 
(CSHMM).  BMC Bioinformatics 2010, 11(Suppl 1):S29.
101. Jiang P, Wu H, Wang W, Ma W, Sun X, Lu Z: MiPred: classification of real 
and pseudo microRNA precursors using random forest prediction 
model with combined features.  Nucleic Acids Res 2007:W339-344.
doi: 10.1186/1471-2164-11-288
Cite this article as: Vaz et al., Analysis of microRNA transcriptome by deep 
sequencing of small RNA libraries of peripheral blood BMC Genomics 2010, 
11:288
